Recently, agents targeting the coinhibitory molecules such as the PD-1/PD-L1 pathway have shown promising results in cancer clinical trials [4, 7–12], indicating a prospect that immunotherapy may play a crucial role in the effective treatments of various types of cancers, including HCC [13–20]. Here, CD274 is linked to cancer.